Maitreya Medica.

Why is Maitreya Medicare Ltd falling/rising?

As of 01-Sep, Maitreya Medicare Ltd's stock price is rising to 120.50, driven by short-term performance and increased investor interest. However, the company faces significant long-term challenges, including weak fundamentals and a negative profit after tax.

As of 01-Sep, Maitreya Medicare Ltd's stock price is rising, currently at 120.50, reflecting a change of 2.2 (1.86%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 2.45% today, indicating a positive market response relative to its peers. Additionally, there has been a notable rise in investor participation, with a delivery volume of 4.4k on 31 August, which has increased by 103.7% compared to the 5-day average. <BR><BR>Despite these positive short-term indicators, it is important to note that the company has weak long-term fundamentals, having not declared results in the last six months and showing a negative profit after tax of Rs -0.89 crore, which has fallen by 166.8%. The company's return on equity is low at 5.47%, suggesting low profitability per unit of shareholders' funds. Furthermore, the stock has experienced significant declines over the past year, with a return of -51.06% and negative operating profits.<BR><BR>In summary, while Maitreya Medicare Ltd's stock is currently rising due to short-term performance and increased investor interest, the underlying long-term challenges and negative financial indicators present a complex picture for potential investors.

Which are the latest news on Maitreya Medica.?

Who are in the management team of Maitreya Medica.?

The management team of Maitreya Medica includes Narendra Singh Tanwar (Managing Director & CFO), Pranav Rohitbhai Thaker and Vimalkumar Natverlal Patel (Whole-time Directors), Hardik Patel and Abha Surana (Independent Directors), and Payal Mathur (Company Secretary & Compliance Officer).

The management team of Maitreya Medica includes the following individuals:<BR><BR>1. Narendra Singh Tanwar - Managing Director & CFO<BR>2. Pranav Rohitbhai Thaker - Whole-time Director<BR>3. Vimalkumar Natverlal Patel - Whole-time Director<BR>4. Hardik Patel - Independent Director<BR>5. Abha Surana - Independent Director<BR>6. Payal Mathur - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Maitreya Medica. do?

Maitreya Medicare Ltd is a micro-cap company in the hospital industry, incorporated in 2019 and rebranded in 2023. As of March 2024, it reported net sales of 12 Cr and a net profit of -1 Cr, with a market cap of INR 77 Cr.

Overview: <BR>Maitreya Medicare Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was originally incorporated as Maitreya Medicare Private Limited in 2019. It underwent a name change to Maitreya Medicare Limited, with the new name officially registered on March 30, 2023. The latest quarterly results reported net sales and net profit for the period ending March 2024.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 12 Cr (Quarterly Results - Mar 2024) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2024) <BR>Market-cap value: INR 77 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 16.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.66 <BR>Return on Equity: -4.37% <BR>Price-to-Book: 2.55 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Maitreya Medica.?

Maitreya Medica's peers include Nephro Care, KHFM Hospitality, Sangani Hospital, Aatmaj Health, Fortis Malar, Shanmuga Hospital, Abate As Industries, Soni Medicare, Aashka Hospitals, and KK Shah Hospital. Maitreya Medica has below-average management risk and capital structure, with a 1-year return of -53.58%, the lowest among its peers.

Peers: The peers of Maitreya Medica. are Nephro Care, KHFM Hospitality, Sangani Hospital, Aatmaj Health, Fortis Malar, Shanmuga Hos., Abate As Indust, Soni Medicare, Aashka Hospitals, and KK Shah Hospital.<BR><BR>Quality Snapshot: Excellent management risk is observed at Nephro Care, while Average management risk is found at Aatmaj Health, Shanmuga Hos., and the rest. Below Average management risk is present at KHFM Hospitality, Maitreya Medica., Sangani Hospital, Fortis Malar, Abate As Indust, Soni Medicare, Aashka Hospitals, and KK Shah Hospital. Growth is Excellent at Nephro Care and Sangani Hospital, Average at Aatmaj Health and Shanmuga Hos., and Below Average at KHFM Hospitality, Maitreya Medica., Fortis Malar, Abate As Indust, Soni Medicare, Aashka Hospitals, and KK Shah Hospital. Capital Structure is Good at Nephro Care, Sangani Hospital, and KK Shah Hospital, Average at Abate As Indust and Aashka Hospitals, and Below Average at KHFM Hospitality, Maitreya Medica., Fortis Malar, Shanmuga Hos., Soni Medicare.<BR><BR>Return Snapshot: Nephro Care has the highest 1-year return at -34.31%, while Maitreya Medica. has the lowest at -53.58%, indicating a worse performance compared to its peers. Additionally, KHFM Hospitality, Sangani Hospital, Aatmaj Health, Fortis Malar, Shanmuga Hos., Abate As Indust, Soni Medicare, Aashka Hospitals, and KK Shah Hospital all have a six-month return of 0.00%.

How big is Maitreya Medica.?

As of 31st August, Maitreya Medicare Ltd has a market capitalization of 77.00 Cr, with recent net sales of 49.48 Cr and a net profit of 4.94 Cr. The balance sheet for March 2025 shows shareholder's funds of 32.08 Cr and total assets of 47.99 Cr.

As of 31st August, Maitreya Medicare Ltd has a market capitalization of 77.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Maitreya Medicare Ltd reported Net Sales of 49.48 Cr and a Net Profit of 4.94 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 32.08 Cr and Total Assets of 47.99 Cr.

Should I buy, sell or hold Maitreya Medicare Ltd?

How has been the historical performance of Maitreya Medica.?

Maitreya Medica's historical performance has shown fluctuations, with net sales declining from 49.41 Cr in Mar'22 to 46.66 Cr in Mar'25, and profits decreasing significantly, while total assets and liabilities increased from 24.49 Cr to 47.99 Cr during the same period. Cash flow improved to 5.00 Cr in Mar'25 after a negative cash flow in Mar'24.

Answer:<BR>The historical performance of Maitreya Medica shows fluctuations in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Maitreya Medica's net sales decreased from 49.41 Cr in Mar'22 to 46.66 Cr in Mar'25, with a notable dip in Mar'24 at 47.80 Cr and a low of 39.38 Cr in Mar'23. Total operating income followed a similar trend, peaking in Mar'22 and declining to 46.66 Cr by Mar'25. The total expenditure, excluding depreciation, decreased from 46.05 Cr in Mar'22 to 41.80 Cr in Mar'25, which contributed to an operating profit (PBDIT) of 5.45 Cr in Mar'25, down from 7.82 Cr in Mar'23. Profit before tax also saw a decline, dropping from 5.93 Cr in Mar'23 to 3.21 Cr in Mar'25, while profit after tax fell from 4.25 Cr in Mar'23 to 1.87 Cr in Mar'25. The earnings per share (EPS) decreased from 8.57 in Mar'23 to 2.76 in Mar'25. On the balance sheet, total assets increased from 24.49 Cr in Mar'22 to 47.99 Cr in Mar'25, while total liabilities rose from 24.49 Cr to 47.99 Cr in the same period. Cash flow from operating activities improved to 5.00 Cr in Mar'25, contrasting with a negative cash flow of -2.00 Cr in Mar'24. Overall, Maitreya Medica has experienced a mixed performance with fluctuations in sales, profits, and cash flow, alongside a significant increase in total assets and liabilities.

Is Maitreya Medica. overvalued or undervalued?

As of August 28, 2025, Maitreya Medica's valuation has improved to attractive, indicating it is undervalued compared to peers like Apollo Hospitals and Max Healthcare, with a PE ratio of 94.15, an EV to EBITDA of 36.98, and a ROCE of 10.49%, while also outperforming the Sensex with a 1-week stock return of 3.55%.

As of 28 August 2025, Maitreya Medica's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 94.15, an EV to EBITDA of 36.98, and a ROCE of 10.49%. <BR><BR>In comparison with peers, Apollo Hospitals, which is also rated attractive, has a significantly lower PE ratio of 70.56, while Max Healthcare is deemed very expensive with a PE of 93.61. This suggests that Maitreya Medica may offer better value relative to its earnings potential. Notably, Maitreya Medica has outperformed the Sensex in the short term, with a 1-week stock return of 3.55% compared to a -2.32% return for the index.

What is the technical trend for Maitreya?

As of June 6, 2025, Maitreya's technical trend is mildly bearish, indicated by a bearish weekly MACD, daily moving averages, and OBV, despite a mildly bullish KST signal.

As of 6 June 2025, the technical trend for Maitreya has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the daily moving averages also indicate a bearish stance. The KST shows a mildly bullish signal, but this is countered by the Dow Theory, which is mildly bearish on a weekly basis. The OBV is also mildly bearish, suggesting selling pressure. Overall, the current technical stance is mildly bearish, with key indicators such as the weekly MACD and daily moving averages driving this outlook.

Who are the top shareholders of the Maitreya?

The top shareholder of Maitreya is Narendra Singh Tanwar, holding 47.02%. Individual investors own 22.01%, with South Gujarat Shares And Sharebrokers Limited as the largest public shareholder at 2.27%, and a foreign institutional investor holding 0.01%.

The top shareholders of Maitreya include the promoters, with Narendra Singh Tanwar holding the largest share at 47.02%. There are no pledged promoter holdings, and individual investors collectively own 22.01% of the company. The highest public shareholder is South Gujarat Shares And Sharebrokers Limited, which holds 2.27%. Additionally, there is one foreign institutional investor (FII) that holds a very small stake of 0.01%.

When is the next results date for Maitreya?

No Upcoming Board Meetings

Has Maitreya declared dividend?

No Dividend History Available